Sign in Subscribe
Diseases

UK Regulator Commits to Overhauling Rulebook for Rare Disease Therapies

Strategic Insights

— 1 min read

Rare diseases affect around 3.5 million people in the UK, with less than 5% having approved treatments. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has set out plans to overhaul the rulebook for rare disease therapies, aiming to make it quicker and easier to get these therapies tested, manufactured, and approved in the UK. The reforms aim to address unique barriers that prevent life-changing rare disease therapies from reaching patients, including small patient numbers and difficult evidence generation.

Key Takeaways:

  • The MHRA's new framework will tackle the unique challenges of rare disease therapies, including small patient numbers and difficult evidence generation.
  • The framework will introduce a new approach to evidence sharing, allowing for the pooling of scarce data and the potential for a single approval for a therapy with a variable component tailored to an individual's characteristics.
  • The MHRA's reforms aim to speed up the path from discovery to delivery, while maintaining strict standards of safety.
  • The reforms are expected to reduce the financial incentive for companies to invest in rare disease therapies, as the current approach makes it costly and inefficient.
  • The new framework will also address the issue of strengthened post-market surveillance, better health system alignment in the UK and internationally, and the importance of maintaining safety.
  • The UK has the potential to become a global leader in rare disease therapies, with a rich academic base and unique datasets provided by the NHS.
  • The reforms are supported by the Rare Disease Consortium, which includes patients, academics, industry, and patient representatives.

Statistics:

  • Around 3.5 million people in the UK live with a rare disease, equivalent to one in 17.
  • Only 5% of rare diseases have approved treatments.
  • The average diagnostic journey takes 5.6 years.
  • 30% of affected children die before the age of five.
  • The cost of delayed diagnosis and limited treatment options is estimated at £340 million annually.
  • The total health-related disability costs are estimated at £4.7 billion.
  • The annual loss to the economy is estimated at £14.9 billion.
  • The new framework aims to reduce the time and costs associated with developing rare disease therapies.

Sources:

  • "New paper sets out UK regulator's intentions to overhaul rulebook for rare disease therapies in UK" by Medicines and Healthcare products Regulatory Agency, published 2 November 2025.
  • "Government's Rare Disease Action Plan" by UK Government.
  • "Life Sciences Sector Plan" by UK Government.
  • "Wellcome NHRS" by Wellcome Trust.

Read more